tbuckley/cabot-search huggingface dataset:
Role of fractalkine (CX3CL1) rich neuroblastoma microenvironments for ganglioside GD2 directed immunotherapy
Authors: H. N. Lode, Y. Zeng, S. Fest, G. Gaedicke
Journal: Journal of Clinical Oncology (2007)

9521 Background: Fractalkine (FKN) is a unique CX3C chemokine (CX3CL1) known to induce adhesion and migration of leukocytes mediated by a membrane-bound and a soluble form. Methods: We found that FKN is expressed in &gt;90% of 68 neuroblastoma (NB) samples as determined by cDNA microarray analysis. FKN expression was inversely correlated with MYCN amplification, suggesting a higher expression of FKN in MYCN non amplified tumors. We characterized the effect of FKN in the neuroblastoma microenvironment in a mouse model. We demonstrate that FKN released from NB cells mediate migration and adhesion of CD4 + -, CD8 + - and NK- cells and subsequent secretion of IFN-γ, in vitro and in vivo. However, the presence of FKN in NB microenvironments did not result in significant anti-NB activity. Results: Targeting of IL-2 into the NB microenvironment using anti-ganglioside GD2 antibody cytokine fusion proteins (ch14.18-IL-2) is currently under clinical evaluation. We investigated a the role of FKN in this context. For this purpose, IL-2 was targeted to GD2 positive NB microenvironments secreting FKN. Only mice bearing FKN and IL2 enriched NB microenvironments exhibited a reduction in primary tumor growth and a complete eradication of experimental liver metastases, in contrast to controls with only FKN or IL-2 enriched NB. This effect was specific since a non-specific antibody-IL-2 fusion protein ch225-IL-2 was ineffective. The mechanisms involved included NK-cell activation by targeted IL-2 into FKN rich NB as indicated by the enhancement of NK-cell mediated lysis using YAC-1 cells as targeted cells. The depletion of NK cells in vivo inhibited the therapeutic effect. Furthermore, co-culture of NXS2-FKN cells and NK cells in vitro induced the expression of IFN-γ by NK cells. However, the depletion of CD8 + T-cells in vivo abrogated the therapeutic effect, and these effector cells showed the highest cytolytic activity against NXS2 target cells in vitro. Finally, only the FKN and IL-2 enriched NB microenvironment resulted in T-cell activation and the release of proinflammatory cytokines. Conclusions: In conclusion our data suggest that targeted IL-2 therapy of FKN rich NB associated with MYCN non-amplified tumors may result in T-cell mediated immune responses. No significant financial relationships to disclose.
Nearly 300 general practices to get premises and IT upgrades
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Nearly 300 general practice surgeries in England are to receive new investment in their buildings and technology infrastructure this year, NHS England has announced.

New money has also been released to expand psychological therapies in primary care and to support indemnity costs of GPs who work for out-of hours services, in the latest phase of investment resulting from NHS England’s General Practice Forward View .1

Announcing the plans at the annual conference of the National Association of Primary Care in Birmingham on Thursday 19 October, NHS England’s chief executive, Simon Stevens, said …
Impact of sarcopenia evaluated using the total psoas area (TPA) in patients undergoing Y-90 radioembolization for hepatocellular carcinoma (HCC).
Authors: Pericles Ioannides, Yazan Abuodeh, Will Jin, Sarah E. Hoffe, Jessica M. Frakes, Richard D. Kim, Junsung Choi, Ghassan E. El-Hadda, Benjamin Biebel, Bela Kis, Jennifer Sweeney, Mark Friedman, Nishi Kothari, Daniel A. Anaya, Kujtim Latifi
Journal: Journal of Clinical Oncology (2016)

217 Background: Severe skeletal muscle depletion, or sarcopenia, is an independent predictor of clinical outcomes in multiple gastrointestinal cancers. This marker of nutritional status has been defined using the TPA which is measured on a single cross sectional CT image at the L4 vertebral body level. We sought to evaluate whether TPA was predictive of outcomes in those patients with unresectable HCC receiving Y-90 radioembolization. Methods: In an IRB approved database consisting of HCC patients treated with Y-90 radioembolization, 111 patients met our selection criteria of treatment from 2009-2014. To be eligible for the study, patients were included prior to their first injection of Y-90 if they had CT imaging available that included the L4 vertebral level that could be transferred to the treatment planning software system. Of these, 73 patients met criteria and were included in the final analysis. The L4 vertebra was identified on axial CT imaging and the psoas muscle was manually contoured bilaterally. Sarcopenia was defined by the presence of the psoas area in less than the median of the cohort. Results: Sarcopenia was associated with a significantly decreased overall survival (p = 0.013) The mean age of the cohort was 67.6 years (range, +/- 9.45) consisting of 84% male and 16% female patients. Difference in age or gender did not correlate significantly with survival. The median survival time in the “low” (sarcopenic) group was 10.46 months (range, +/- 1.21), whereas the median survival in the “high” group was 18.02 months (range, +/-4.26). The median survival for the entire cohort was 12.86 months. OS at 30 months was 15.4% in the sarcopenic group and 30.2 % in the “high” group. TPA in the upper quartile was associated with a survival benefit compared to the bottom quartiles. The presence of sarcopenia was associated with an increased risk of mortality (HR = 2.049; p = 0.015 CI: 01.150, 3.649). Conclusions: Measurement of the psoas area using TPA is a simple objective method to detect frailty and is predictive of overall survival outcome following Y-90 radioembolization
Genetic Variability In the Transcriptional Factor EP300 Strongly Influences the Clinical Outcome of Allogeneic Stem Cell Transplantation (Allo-SCT)
Authors: Beatriz Martin-Antonio, Rocio Cardesa, Isabel Álvarez, Francisco Márquez-Malaver, Alicia Báez, Magdalena Carmona, Jose Falantes, Francesc fernandez-Aviles, Carmen Martinez, Montserrat Rovira, Ildefonso Espigado, Alvaro Urbano-Ispizua
Journal: Blood (2010)
Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.
Authors: Jason R. Westin, Michael A. Thompson, Vince D. Cataldo, Bela B. Toth, Perpetua Sanjorjo, Scott Bourgeois, Camilo Jimenez, William A. Murphy, Michelle Fanale, Luis Fayad, Nathan Fowler, Larry Kwak, Peter McLaughlin, Sattva Neelapu, Barbara Pro, Alma Rodriguez, Jatin Shah, Fredrick B. Hagemeister
Journal: Blood (2009)
Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway
Authors: J Xin, D You, P Breslin, J Li, J Zhang, W Wei, J Cannova, A Volk, R Gutierrez, Y Xiao, A Ni, G Ng, R Schmidt, Z Xia, J Pan, H Chen, M M Patel, P C Kuo, S Nand, A R Kini, J Zhang, J Chen, J Zhu, J Zhang
Journal: Leukemia (2016)
Landscape of DNA Methylation and Genetic Profiles in 291 Patients with Myelodysplastic Syndromes
Authors: Yasunobu Nagata, Hiromichi Suzuki, Vera Grossmann, Genta Nagae, Yusuke Okuno, Ulrike Bacher, Susanne Schnittger, Yusuke Shiozawa, Tetsuichi Yoshizato, Tamara Alpermann, Kenichi Yoshida, Keisuke Kataoka, Niroshan Nadarajah, Andreas Roller, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Alexander Kohlmann, Claudia Haferlach, Tsutomu Sato, Chikara Hirase, Nobuaki Dobashi, Toru Kiguchi, Shigeru Chiba, Shigeki Ohtake, Hitoshi Kiyoi, Yukio Kobayashi, Tomoki Naoe, Satoru Miyano, Wolfgang Kern, Hideki Makishima, Hiroyuki Aburatani, Yasushi Miyazaki, Torsten Haferlach, Seishi Ogawa
Journal: Blood (2015)
Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results
Authors: Paola Bertazzoni, Cristina Rabascio, Liliana Calabrese, Federica Gigli, Simona Bassi, Luca Nassi, Simona Sammassimo, Sara Steffanoni, Davide Radice, Angelica Calleri, Emilia Cocorocchio, Daniele Laszlo, Giovanni Martinelli
Journal: Blood (2008)
Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Authors: Stefan Faderl, Alessandra Ferrajoli, William Wierda, Farhad Ravandi, Susan O’Brien, Guillermo Garcia-Manero, Deborah A. Thomas, Mary L. Browning, Michael J. Keating
Journal: Blood (2005)
Hematopoietic stem cell transplantation (HSCT) in patients with primary granulocytic sarcoma (GS)
Authors: M. Hentrich, G. Ledderose, L. Lutz, J. Tischer, A. Gerl, R. C. Hartenstein, H. J. Kolb
Journal: Journal of Clinical Oncology (2006)

16529 Background: GS preceding acute myeloid leukemia (AML) is extremely rare and the prognosis is poor. Patients usually undergo systemic chemotherapy (CT) but the role of HSCT is not sufficiently defined. Methods: We report on 3 cases of non-leukemic GS, all of those treated with inductive CT followed by either autologous or allogeneic SCT. Furthermore, the literature on the role of HSCT in GS is reviewed. Results: Case 1: A 55-year-old man presented with a mediastinal mass and right pleural effusion. Fluid cytology revealed hematopoietic cells. Mediastinoscopy showed GS but peripheral blood and bone marrow were free of blasts. He underwent 2 cycles of anthracyline-cytarabine (AC) containing induction CT followed by myeloablative conditioning and autologous SCT in 1 st remission. Radiotherapy to the mediastinum was applied afterwards. He remained in CR for 6 months when a leukemic relapse was diagnosed. He is currently undergoing reinduction CT and will proceed to receive an unrelated donor (URD) SCT. Case 2: A 51-year old man was diagnosed with GS of the right testicle. After orchiectomy he was followed by observation only. 8 months later a leukemic relapse [karyotype 46 XY, del (9)(q22), der(13) t(8;13)] occurred. The patient received 2 courses of AC-based induction CT followed by myeloablative conditioning and an HLA-matched URD transplant in 1 st CR. However, 27 months after HSCT another leukemic relapse was diagnosed. He received a 2 nd URD transplant but died of severe graft versus host disease (GvHD) and veno-occlusive disease 10 weeks later. Case 3: A 37 year-old woman was diagnosed with non-leukemic GS located at multiple bone sites. She underwent 4 courses of AC-containing CT resulting in a CR. 6 months later she presented with multiple recurrent GS confined to the skeleton. She received myeloablative conditioning followed by an allogeneic SCT from her HLA-mismatched brother. Another CR was attained. However, she suffered from severe GvHD and died of severe sepsis 3 months after HSCT. Conclusions: The outcome of patients with primary GS appears to be poor even after treatment with HSCT. However, allogeneic SCT has curative potential as indicated by some cases of successful transplants reported in the literature. No significant financial relationships to disclose.
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
Authors: J.-Y. Pierga, F.-C. Bidard, A. Autret, T. Petit, F. Andre, F. Dalenc, C. Levy, J.-M. Ferrero, G. Romieu, J. Bonneterre, F. Lerebours, T. Bachelot, P. Kerbrat, M. Campone, J.-C. Eymard, M.-A. Mouret-Reynier, J. Gligorov, A.-C. Hardy-Bessard, A. Lortholary, P. Soulie, J.-M. Boher, C. Proudhon, E. Charafe-Jaufret, J. Lemonnier, F. Bertucci, P. Viens
Journal: Annals of Oncology (2016)
Natriuretic peptides and peripheral autonomic neurotransmission: back to the A, B, and C’s.
Authors: Olujimi A. Ajijola, Kalyanam Shivkumar, Beth A. Habecker
Journal: Cardiovascular Research (2016)

This editorial refers to ‘C-type natriuretic peptide and natriuretic peptide receptor NPR-B signalling inhibits cardiac sympathetic neurotransmission and autonomic function’ by J. Buttgereit et al. , pp. 637–644. 

Natriuretic peptides (NPs) are a family of secretory peptides that have in common a ringed amino-acid structure linked by disulphide bonds1 which signal via NP receptors (NPRs). Three primary members have been identified: atrial NP (ANP), brain-derived NP (BNP), and C-type NP (CNP), but there is a closely related forth peptide Dendroaspis NP (DNP). ANP and BNP are elevated by atrial stretch; ventricular stretch or stress elevates BNP levels; and all NPs are increased in heart failure (HF). The NPRs are particulate guanylyl-cyclase-coupled receptors which stimulate production of cGMP. Of the seven NPR isoforms known to exist, the majority of NP physiological actions are mediated via NPR-A and -B, while NPR-C mediates NP degradation. ANP, BNP, and DNP activate NP receptor A (NPR-A), which increases natriuresis and vasodilation. In contrast, CNP specifically activates NPR-B and does not possess the potent diuretic actions of the other NPs.

Although extensive studies have been performed on BNP in the context of HF, where it has been utilized both as a diagnostic and as a potential therapeutic tool,2 newer data implicate the peptide in modulating peripheral autonomic neurotransmission. BNP activation of NPR-A inhibits neurotransmission from sympathetic neurons by decreasing …
Review: Acupuncture reduces migraine frequency more than usual care, sham acupuncture, or prophylactic drugs
Authors: Alexander W. Chessman
Journal: Annals of Internal Medicine (2016)

ACP Journal Club18 October 2016Review: Acupuncture reduces migraine frequency more than usual care, sham acupuncture, or prophylactic drugsAlexander W. Chessman, MDAlexander W. Chessman, MDMedical University of South Carolina, Charleston, South Carolina, USA (A.W.C.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-165-8-044 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationLinde K, Allais G, Brinkhaus B, et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev. 2016;6:CD001218. https://pubmed.ncbi.nlm.nih.gov/27351677Clinical Impact RatingsGIM/FP/GP: Neurology: References1 Linde K, Niemann K, Schneider A, Meissner K. How large are the nonspecific effects of acupuncture? A meta-analysis of randomized controlled trials. BMC Med. 2010;8:75. [PMID: 21092261] Google Scholar2 Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008;336:999−1003. [PMID: 18390493] Google Scholar Author, Article, and Disclosure InformationAffiliations: Medical University of South Carolina, Charleston, South Carolina, USA (A.W.C.)This article was published at Annals.org on 4 October 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byInitiation of Acupoint Molecular Mechanisms for Manual Acupuncture Analgesia—Nuclear Factor κB Signaling PathwayBaseline Brain Gray Matter Volume as a Predictor of Acupuncture Outcome in Treating MigraineAcupuncture Reversible Effects on Altered Default Mode Network of Chronic Migraine Accompanied with Clinical Symptom ReliefIn Cochrane Review, Acupuncture Found to Reduce Episodic Migraine More Than Usual Care or Sham Acupuncture 18 October 2016Volume 165, Issue 8Page: JC44KeywordsAcupunctureAdverse eventsDrugsGrading of Recommendations Assessment Development and EvaluationHeadachesMigraineOdds ratioQuality of lifeSafetySecondary headaches ePublished: 18 October 2016 Issue Published: 18 October 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Clinical Characteristics, Chromosomal Abnormalities and Outcomes in Very Elderly Patients with Multiple Myeloma: The IFM Experience
Authors: Cyrille Hulin, Philippe Rodon, Loic Campion, Murielle Roussel, Xavier Leleu, Gerald Marit, Denis Caillot, Bruno Royer, Brigitte Kolb, Mamoun Dib, Laurent Voillat, Brigitte Pegourie, Marc Wetterwald, Laurent Garderet, Lotfi Benboubker, Olivier Decaux, Carine Chaleteix, Catherine Traulle, Margaret Macro, Philippe Moreau, Herve avet-Loiseau
Journal: Blood (2012)
Delaying surgery for obese patients or smokers is a bad idea
Authors: David Shaw
Journal: BMJ (2016)

Targeting specific groups of patients is illogical and unethical, says David Shaw 

It was recently reported that Vale of York Clinical Commissioning Group planned to delay all elective surgery for obese patients for a year until they lost 10% of their weight and to smokers for six months unless they stopped smoking for eight weeks.1 The overall rationale for this policy and the clinical rationale for targeting these particular groups are unclear.

The most obvious objection to the policy is that it is unfair to target specific groups of patients in this way. Why should obese people and smokers be singled out? The rationale cannot be clinical risk: though surgery is riskier for morbidly obese patients, and smoking is bad for your health in the long term, mildly obese patients and smokers are just as likely …
PTP-1B Is the Protein Tyrosine Phosphatase That Initiates Integrin αIIbβ3 Outside-In Signaling in Platelets.
Authors: Elena G. Arias-Salgado, Fawaz Haj, Christophe Dubois, Barbara C. Furie, Bruce Furie, Benjamin G. Neel, Sanford J. Shattil
Journal: Blood (2004)
Phase II study of irinotecan (cpt-11) and cisplatin (cddp) regimen (IP) with concurrent thoracic radiotherapy (TRT) in limited-stage small cell lung cancer (LS-SCLC)
Authors: D. Castellano, A. Bartolomé, A. Font, A. Lopez-Martín, P. Diz, M. Lopez-Brea, P. Garrido, P. Lianes, H. Cortés Funes, L. Paz-Ares
Journal: Journal of Clinical Oncology (2006)

7084 Background: the combination of CPT-11 and CDDP (IP) is an active regimen for SCLC. (Noda et al NEJM ’02, Hanna et al ASCO 2005). We performed a multicenter phase II study to assess the efficacy and toxicity of IP regimen with concurrent TRT in previously untreated LS-SCLC pts. Methods: Eligible pts were required to have histologically confirmed SCLC, measurable disease, no prior therapy, ECOG PS of 0–2, adequate organ functions, and to give informed consent. Treatment consisted of: CDDP 60 mg/m 2 D1, I 60mg/m 2 IV D1, 8 Q 21D for 4 cycles, and concurrent TRT 2.0 Gy daily to a total of 60.0 Gy, beginning with the 2nd cycle. I was adjusted to 50 mg/m 2 at 2nd and 3rd cycles (during TRT). Pts were restaged after 4 cycles. Pts without progression or undue toxicity received 2 additional cycles. PCI (2.0 Gy X 10) was offered to CR pts. The primary endpoints were response rate and OS. Results: Twenty-six pts were included and 25 pts were evaluable for response (median age 62; M/F, 22/4; PS 0/1/2, 9/17; T 2–4 N 0, T 2–4 N + 6/20pts). Among 126 cycles administered, the relative dose-intensities of I and CDDP were 80% and 92% respectively. Median number of cycles/pt was 5 (1–6), and 22 pts completed the IP + TRT program. Fifteen pts achieved a CR and 6 pts a PR, for an overall RR of 84%. Median TTP was 12 months. At a median follow-up of 14 months, 19 pts are alive, and estimated median survival is 17 months. Grade 3–4 (NCI-CTC 3.0) toxicity (per cycle) during concurrent therapy included: neutropenia (25%), anemia (3%), thrombocytopenia (3%), diarrhea (10%), vomiting (5%), esophagitis (10%). There were no treatment-related deaths. Two pts required hospitalization during the concurrent therapy due to g3 diarrhea (1 pt) and febrile neutropenia (1 pt). Conclusions: The concurrent regimen of IP + TRT is highly effective in pts with LS-SCLC. The associated toxicity profile is predictable and adequate. Further study is warranted. No significant financial relationships to disclose.
Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer
Authors: M. Nishio, F. Ohyanagi, A. Horikike, Y. Okano, Y. Satoh, O. Sakae, Y. Ishikawa, K. Nakagawa, K. Nakagawa, T. Horai
Journal: Journal of Clinical Oncology (2007)

7718 Background: Gemcitabine and irinotecan has been shown to have an antitumor activity as a single agent against previously treated SCLC. The objective of this study was to assess the efficacy and safety of gemcitabine combined with irinotecan in patients with refractory or relapsed SCLC. Methods: Patients with histologically or cytologically confirmed SCLC, 20 to 74 years in age, performance status 0–2, with a history of receiving one platinum-based chemotherapy were eligible for the study. Treatment consisted of gemcitabine (1,000 mg/m 2 ) and irinotecan (150 mg/m 2 ) on days 1 and 15 of a 28-day cycle.The primary endpoint was the response rate (RR), and planned sample size for this phase II study was 30 patients (Simon's two-stage minimax design). Results: Thirty-one patients were enrolled and 30 patients (24 males/6 females, 10 refractory/20 sensitive, median age, 65 years) receive protocol treatment in this phase II trial. The median treatment cycles were 3 (1–10). The overall response rates was obtained in 39.3% (95% CI: 18.1% to 60.5%) of the patients, including two patients with refractory disease and 9 patients with sensitive disease. The median overall survival time was 14.4 months, and the 1-year survival rate was 51%. The median survival time of the patients with refractory disease was 7.4 months, compared with 14.4 months for patients with sensitive disease. The chief grade 3/4 toxicities included neutropenia (42%), thrombocytopenia (3%), diarrhea (9%), and liver dysfunction (3%). The only grade 4 toxicities were one case of grade 4 neutropenia (3.3%) and one case of grade 4 thrombocytopenia (3.3%). Conclusion: Gemcitabine plus irinotecan is an active regimen that seems to be well- tolerated by patients with previously treated SCLC. No significant financial relationships to disclose.
Deep Learning in Medical Image Analysis
Authors: Dinggang Shen, Guorong Wu, Heung-Il Suk
Journal: Annual Review of Biomedical Engineering (2017)

This review covers computer-assisted analysis of images in the field of medical imaging. Recent advances in machine learning, especially with regard to deep learning, are helping to identify, classify, and quantify patterns in medical images. At the core of these advances is the ability to exploit hierarchical feature representations learned solely from data, instead of features designed by hand according to domain-specific knowledge. Deep learning is rapidly becoming the state of the art, leading to enhanced performance in various medical applications. We introduce the fundamentals of deep learning methods and review their successes in image registration, detection of anatomical and cellular structures, tissue segmentation, computer-aided disease diagnosis and prognosis, and so on. We conclude by discussing research issues and suggesting future directions for further improvement.
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals
Authors: Marta Coscia, Francesca Pantaleoni, Chiara Riganti, Candida Vitale, Micol Rigoni, Silvia Peola, Daniela Drandi, Barbara Castella, Marina Ruggeri, Paola Omedè, Marco Ladetto, Amalia Bosia, Mario Boccadoro, Massimo Massaia
Journal: Blood (2010)
Erratum: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy (New England Journal of Medicine (April 18, 2002) 346 (1185-1193))
Authors: S Hacein-Bey-Abina, F Le Deist, F Carlier, C Bouneaud, C Hue, JP De Villartay, AJ Thrasher, N Wulffraat, R Sorensen, S Dupuis-Girod, A Fischer, E Graham Davies, W Kuis, L Leiva, M Cavazzana-Calvo
Journal: New England Journal of Medicine (2002)
Killer Immunoglobulin-Like Receptor Ligand (KIR-Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM).
Authors: J. Shi, S. Szmania, N. Rosen, A. Moreno, R. Walker, B. DuPont, K. Hsu, L.A. Baxter-Lowe, J. Shaughnessy, B. Barlogie, M. Cottler-Fox, G. Tricot, F. van Rhee
Journal: Blood (2005)